Topotecan in pediatric patients with recurrent and progressive solid tumors: A pediatric oncology group phase II study

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 4, 1998, Pages 315-318

  Nitschke, Ruprecht ^a,f,g   Parkhurst, Joan ^a   Sullivan, James ^b   Harris, Michael B ^c   Bernstein, Mark ^e   Pratt, Charles ^d  

^a OKLAHOMA CITY UNIVERSITY   (United States)

^b Pediat Oncol Grp Stat Office   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d St Jude Children's Research   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f Children's Hospital Oklahoma City   (United States)

^g c/o Pediatric Oncology Group ^*  (United States)

Author keywords

Pediatric solid tumor; Phase II study; Topotecan

Indexed keywords

DIPHENHYDRAMINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HYDROCORTISONE; ONDANSETRON; TOPOTECAN;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CHILD; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS; INFANT; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0031759531     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199807000-00006     Document Type: Article

References (10)

1. Pommier Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol 1996;23 (Suppl 3):3-10.
2. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
3. Kudelka A, Tresukosol D, Edwards C, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-7.
4. Schiller J, Kim K, Hutson P. Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996;14:2342-52.
5. Tubergen D, Stewart C, Pratt C, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group Study. J Pediatr Hematol Oncol 1996;18:352-61.
6. Kretschmar C, Kletzel M, Murray K, et al. Upfront phase II therapy with taxol (Tx1) and topotecan (Topo) in untreated children (> 365 days) with disseminated (INSS stage 4) neuroblastoma (NB). A Pediatric Oncology Group (POG) Study. Med Pediatr Oncol 1995;25:243.
7. Vietti T, Crist W, Ruby E, et al. for the Intergroup RMS Study Group (IRSG). Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study. Proc Amer Soc Clin Oncol 1997;16:510a.
8. Saylors RL, Stewart C, Wall D, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group study. J Clin Oncol 1998;16:945.
9. POG #9464. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors. A Pediatric Oncology Group phase II study. [Personal communication].
10. POG #9461. Randomized treatment of refractory neuroblastoma with topotecan regimens, following deferoxamine (POG only) in an investigational window: a POG/CCG phase II intergroup study. [Personal communication].